Table 1:

Characteristics of 130 325 patients who started allopurinol during the study period, by presence of heart disease

CharacteristicNo. (%) of patients*Standardized mean difference
Heart disease
n = 28 176
No heart disease
n = 102 149
Age, yr0.80
 Mean ± SD70.2 ± 11.659.9 ± 14.0
 < 605401 (19.2)48 494 (47.5)
 60–707301 (25.9)27 271 (26.7)
 ≥ 7015 454 (54.9)26 384 (25.8)
Sex, female9328 (33.1)27 870 (27.3)0.13
Region0.21
 Richmond1010 (3.6)4574 (4.5)
 Vancouver and Fraser North9414 (33.4)24 994 (24.5)
 North Shore and Fraser South5687 (20.2)20 998 (20.6)
 Remainder12 065 (42.8)51 583 (50.5)
Comorbidities
 Ischemic heart disease24 537 (87.1)03.67
 Heart failure10 076 (35.8)01.06
 Chronic kidney disease7138 (25.3)8736 (8.6)0.46
 Diabetes12 111 (43.0)20 759 (20.3)0.50
 Gout18 104 (64.3)61 660 (60.4)0.08
Medications
 Diuretics16 415 (58.3)26 124 (25.6)0.70
 Initial allopurinol dosage > 100 mg/d16 333 (58.0)66 520 (65.1)0.15
  • Note: SD = standard deviation.

  • * Unless stated otherwise.

  • Standardized mean differences > 0.1 are considered meaningful.

  • Regions are grouped by proportion of Asian people in the population according to data from the 2016 Canadian Census (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.190339/-/DC1) and are used here as a surrogate for Asian race, which has the highest prevalence of the HLA-B*5801 polymorphism.